Europe Anatomic Pathology Market

Market Introduction

The anatomic pathology is a significant part of the study and treatment of the diseases. Anatomic pathology is a broad field that includes decedent pathology, surgical pathology, cytopathology, neuropathology, and ophthalmic pathology. The anatomic pathology is usually performed in the medical laboratories of hospitals and diagnostics laboratories.

Europe Anatomic Pathology Strategic Insights

Strategic insights for the Europe Anatomic Pathology provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Anatomic Pathology Report Scope

Europe Anatomic Pathology Regional Insights

The geographic scope of the Europe Anatomic Pathology refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe anatomic pathology market is expected to reach US$2,095.39 million by 2028 from US$ 1,351.47 million in 2021; it is estimated to grow at a CAGR of 6.1% from 2021 to 2028. The growth of the market is attributed to key driving factors such as the increasing prevalence of cancer and other diseases and the growing focus on personalized medicines. However, the lack of skilled professionals and the implementation of stringent government regulations hinder the market growth.

Personalized medicines are mainly designed by considering individuals’ genetic profiles to guide decisions made with respect to the prevention, diagnosis, and treatment of a disease. They provide an opportunity for medical device and drug manufacturers to develop agents that are targeted to patient groups that do not respond to medications as intended or that do not respond as expected to the traditional healthcare practices. There is much evidence indicating that a substantial portion of the variability in drug response depends on factors that are genetically controlled, e.g., age, nutrition, environmental exposure, and health status. Genomics plays an important role in the emergence of personalized medicines, as having the knowledge of a patient's genetic profile would help doctors in selecting an apt medication. Personalized medicines are useful for improving healthcare by enabling each patient to receive earlier diagnoses, risk assessments, and optimal treatments. The pathologists play an important role in developing and implementing molecular and genomic tests in practice. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. The personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for more specific action. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even greater potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is boosting the anatomic pathology market growth. Also, the rising number of clinical trials for the anticancer drugs is likely to fuel the growth of the Europe anatomic pathology market in the coming years.

Europe is facing the massive impact of the COVID-19 outbreak due to the exponential growth in the number of COVID-19 infected patients in the region. The pandemic is compounding workforce pressures across the European nations. The impact of the pandemic on cancer patients is high in terms of anxiety, fear, and psychological distress. Moreover, the supply of diagnostics kits and assays is delayed because of the increase in quarantine time and the shutdown of all business operations. There has been a decrease in patients seeking help for their symptoms—including a significant decline in referrals from primary care—leading to substantial delays in diagnosis and a significant backlog of cases. Moreover, a recent report from Cancer Research UK, while estimating the cost of growing the NHS cancer workforce in England by 2029, shows that the number of histopathologists is set to reduce from the existing shortfall by an additional 2% by 2029. However, the European Society for Medical Oncology (ESMO) is encouraging medical oncologists to work closely with governments and health authorities to sustain high-quality cancer services in clinics and hospitals.

Key Market Segments

Based on product and service, the Europe anatomic pathology market is segmented into instruments, consumables, and services. The services segment held the largest share of the market in 2021, whereas the instruments segment is anticipated to register the highest CAGR of the market during the forecast period.

By application, the Europe anatomic pathology market is segmented into disease diagnosis, drug discovery and development, and others. The disease diagnosis segment held the largest market share in 2021. However, the drug discovery and development segment is anticipated to register the highest CAGR of the market during 2021–2028.

The Europe anatomic pathology market, based on end user, is segmented into hospitals, research laboratories, diagnostic laboratories, and others. The others segment consists of pharmaceutical and biotechnology companies and contract research organizations (CROs). The hospitals segment held the largest share of the market in 2021, and the diagnostic laboratories segment is anticipated to register the highest CAGR of the market during the forecast period.

Major Sources and Companies Listed

A few of the primary and secondary sources referred to while preparing the report on the Europe anatomic pathology market are the Centers for Disease Control and Prevention (CDC), European Society for Medical Oncology (ESMO), and World Health Organization (WHO).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of Europe anatomic pathology market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Europe anatomic pathology market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Europe anatomic pathology market.

EUROPE ANATOMIC PATHOLOGY MARKET SEGMENTATION

By

Product

s and Services

• Services
• Consumables
• Instruments

By

Application

• Disease Diagnosis
• Drug Discovery and Development
• Others

By End User

• Hospitals
• Research Laboratories
• Diagnostic Laboratories
• Others

By Country

• Germany
• Russia
• France
• Italy
• UK
• Rest of Europe

Company Profiles

• F. HOFFMANN-LA ROCHE LTD.
• Danaher
• Hologic, Inc.
• Agilent Technologies, Inc.
• BioGenex
• Diapath S.p.A.
• Bio SB
• MERCK KGaA
• BD
• PHC Holdings Corporation